Global epidemiology and control strategies of Chikungunya virus: a review
10.16250/j.32.1915.2025138
- VernacularTitle:基孔肯雅病毒全球流行态势与防控策略研究进展
- Author:
Heng RONG
1
;
Yuhan DING
1
;
Shuo NING
1
;
Yiyue GE
1
;
Lunbiao CUI
1
Author Information
1. National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Center for Disease Control and Prevention, Nanjing, Jiangsu 210009, China
- Publication Type:Journal Article
- Keywords:
Chikungunya virus;
Chikungunya fever;
Epidemic trend;
Diagnostic technology;
Vaccine
- From:
Chinese Journal of Schistosomiasis Control
2025;37(5):455-464
- CountryChina
- Language:Chinese
-
Abstract:
Chikungunya virus (CHIKV), which is primarily transmitted by Aedes aegypti and Ae. albopictus, has recently rapidly spread across the world, which poses a huge threat to public health. Chikungunya fever (CHIKF), caused by CHIKV infection, typically manifests as acute febrile illness with severe polyarthralgia that may persist for months to years. A few severe CHIKF cases may be accompanied by serious neurological complications, even resulting in death. The accelerating global expansion of CHIKV is closely associated with genetic variations of the virus, and mutated genes in CHIKV may augment the virus adaptability to Aedes vectors and transmission efficiency. Currently, the diagnosis of the CHIKV infection primarily relies on molecular and serological assays; however, there are still multiple challenges for early and differential diagnosis of CHIKV infections due to co-infections with arboviruses and nonspecific early symptoms. The first prophylactic vaccine for CHIKF has been recently approved in the United States; however, the large-scale application still awaits further validations. More importantly, there are no licensed antiviral therapies against CHIKV until now. This review describes the structure and pathogenesis of CHIKV, summarizes the latest epidemiology and advances in the diagnosis of CHIKV infections, and depicts the current status and prospects of antiviral agents and vaccine development, so as to inform evidence-based prevention and control strategies.
